Laboratory Question for the Week of March 28, 2016

Laboratory Compliance Question of the Week

Question:

How will Medicare reimburse the screening test for cervical cancer with human papillomavirus (HPV) when reported with G0476? 

Answer:

Claims with dates of service from July 9, 2015 through December 31, 2016 will be priced by Medicare administrative contractors. Beneficiary coinsurance and deductibles will not be applied to claim lines containing the following code: 

G0476 Infectious agent detection by nucleic acid (DNA or RNA); human papillomavirus (HPV), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test

Beginning January 1, 2017, the code will be priced and paid according to the Clinical Laboratory Fee Schedule (CLFS).

Disclaimer: Every reasonable effort was made to ensure the accuracy of this information at the time it was published. However, due to the nature of industry changes over time we cannot guarantee its validity after the year it was published.